Relmada Therapeutics Statistics
NASDAQ: RLMDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
3.25-0.03 (-0.91%)
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Relmada Therapeutics by the numbers
Relmada Therapeutics has a market capitalization of $346.7 million based on 106.67M shares outstanding. With trailing EPS of $-0.91, Relmada Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 27.1% below its 50-day average and 40.4% below its 200-day average.
Average daily trading volume is 1.34M shares, or about $4.4 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
RLMD valuation vs. peer median
| Metric | RLMD | Peer median | Difference |
|---|---|---|---|
| Market cap | $346.68M | $362.66M | -4% |
| Avg. volume | 1.34M | 663.32K | +102% |
Peer median across 8 companies: ENTA, EBS, ARCT, GALT, IRD, TTRX, CYPH, BNTC.
Valuation
- Market cap
- $346.68M
- EPS (TTM)
- $-0.91
- Shares outstanding
- 106.67M
Price and trading
- Previous close
- 3.28
- Open
- 3.26
- Day range
- 3.24 – 3.35
- 52-week range
- 1.80 – 8.00
- 52-week change
- +63.32%
- Beta
- —
- Volume
- 1.50M
- Average volume
- 1.34M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Aug 6, 2026
Additional statistics
- Market Cap
- 346.68M
- Forward Pe
- -7.93
- Eps
- -0.91
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 8.00
- Week52 Low
- 1.80
- Avg Volume
- 1.34M
- Shares Outstanding
- 106.67M
- Ma50
- 4.46
- Ma200
- 5.45
- Earnings Date
- Aug 6, 2026
- Pct From52w High
- -59.37%
- Pct From52w Low
- 80.26%